Open258.440 | Close257.520 |
Vol / Avg.806.443K / 1.004M | Mkt Cap37.295B |
Day Range255.160 - 261.375 | 52 Wk Range194.690 - 334.580 |
Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.
Open258.440 | Close257.520 |
Vol / Avg.806.443K / 1.004M | Mkt Cap37.295B |
Day Range255.160 - 261.375 | 52 Wk Range194.690 - 334.580 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 4.000 | (EXPECTED) 2023-10-24 | |||||
REV | 2.390B |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.770 | 4.020 | 0.2500 | ||||
REV | 2.370B | 2.456B | 86.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-06 | HSBC | Morten Herholdt | Initiates Coverage On | Buy | Announces | - | 360.00 |
2023-09-05 | Morgan Stanley | Matthew Harrison | Maintains | OverweightOverweight | Raises | 363.00 | 381.00 |
2023-08-29 | RBC Capital | Brian Abrahams | Maintains | OutperformOutperform | Raises | 354.00 | 357.00 |
2023-08-14 | Mizuho | Salim Syed | Maintains | BuyBuy | Lowers | 340.00 | 335.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIIB | Biogen | -0.21% | 37.3B |
LEGN | Legend Biotech | 5.66% | 12.4B |
EXAS | Exact Sciences | 1.55% | 12.2B |
SRPT | Sarepta Therapeutics | 3.37% | 11.5B |
NBIX | Neurocrine Biosciences | 0.7% | 11.3B |
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Biogen (NASDAQ: BIIB) was reported by HSBC on Wednesday, September 6, 2023. The analyst firm set a price target for 360.00 expecting BIIB to rise to within 12 months (a possible 39.79% upside). 87 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $257.52 last updated September 27, 2023 at 8:00 PM UTC.
There is no dividend information for Biogen.
Biogen’s Q3 earnings are confirmed for Tuesday, October 24, 2023.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.
Open258.440 | Close257.520 |
Vol / Avg.806.443K / 1.004M | Mkt Cap37.295B |
Day Range255.160 - 261.375 | 52 Wk Range194.690 - 334.580 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 4.000 | (EXPECTED) 2023-10-24 | |||||
REV | 2.390B |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.770 | 4.020 | 0.2500 | ||||
REV | 2.370B | 2.456B | 86.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-06 | HSBC | Morten Herholdt | Initiates Coverage On | Buy | Announces | - | 360.00 |
2023-09-05 | Morgan Stanley | Matthew Harrison | Maintains | OverweightOverweight | Raises | 363.00 | 381.00 |
2023-08-29 | RBC Capital | Brian Abrahams | Maintains | OutperformOutperform | Raises | 354.00 | 357.00 |
2023-08-14 | Mizuho | Salim Syed | Maintains | BuyBuy | Lowers | 340.00 | 335.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIIB | Biogen | -0.21% | 37.3B |
LEGN | Legend Biotech | 5.66% | 12.4B |
EXAS | Exact Sciences | 1.55% | 12.2B |
SRPT | Sarepta Therapeutics | 3.37% | 11.5B |
NBIX | Neurocrine Biosciences | 0.7% | 11.3B |
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Biogen (NASDAQ: BIIB) was reported by HSBC on Wednesday, September 6, 2023. The analyst firm set a price target for 360.00 expecting BIIB to rise to within 12 months (a possible 39.79% upside). 87 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $257.52 last updated September 27, 2023 at 8:00 PM UTC.
There is no dividend information for Biogen.
Biogen’s Q3 earnings are confirmed for Tuesday, October 24, 2023.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.
Open258.440 | Close257.520 |
Vol / Avg.806.443K / 1.004M | Mkt Cap37.295B |
Day Range255.160 - 261.375 | 52 Wk Range194.690 - 334.580 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 4.000 | (EXPECTED) 2023-10-24 | |||||
REV | 2.390B |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.770 | 4.020 | 0.2500 | ||||
REV | 2.370B | 2.456B | 86.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-06 | HSBC | Morten Herholdt | Initiates Coverage On | Buy | Announces | - | 360.00 |
2023-09-05 | Morgan Stanley | Matthew Harrison | Maintains | OverweightOverweight | Raises | 363.00 | 381.00 |
2023-08-29 | RBC Capital | Brian Abrahams | Maintains | OutperformOutperform | Raises | 354.00 | 357.00 |
2023-08-14 | Mizuho | Salim Syed | Maintains | BuyBuy | Lowers | 340.00 | 335.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIIB | Biogen | -0.21% | 37.3B |
LEGN | Legend Biotech | 5.66% | 12.4B |
EXAS | Exact Sciences | 1.55% | 12.2B |
SRPT | Sarepta Therapeutics | 3.37% | 11.5B |
NBIX | Neurocrine Biosciences | 0.7% | 11.3B |
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Biogen (NASDAQ: BIIB) was reported by HSBC on Wednesday, September 6, 2023. The analyst firm set a price target for 360.00 expecting BIIB to rise to within 12 months (a possible 39.79% upside). 87 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $257.52 last updated September 27, 2023 at 8:00 PM UTC.
There is no dividend information for Biogen.
Biogen’s Q3 earnings are confirmed for Tuesday, October 24, 2023.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.
Open258.440 | Close257.520 |
Vol / Avg.806.443K / 1.004M | Mkt Cap37.295B |
Day Range255.160 - 261.375 | 52 Wk Range194.690 - 334.580 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 4.000 | (EXPECTED) 2023-10-24 | |||||
REV | 2.390B |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.770 | 4.020 | 0.2500 | ||||
REV | 2.370B | 2.456B | 86.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-06 | HSBC | Morten Herholdt | Initiates Coverage On | Buy | Announces | - | 360.00 |
2023-09-05 | Morgan Stanley | Matthew Harrison | Maintains | OverweightOverweight | Raises | 363.00 | 381.00 |
2023-08-29 | RBC Capital | Brian Abrahams | Maintains | OutperformOutperform | Raises | 354.00 | 357.00 |
2023-08-14 | Mizuho | Salim Syed | Maintains | BuyBuy | Lowers | 340.00 | 335.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIIB | Biogen | -0.21% | 37.3B |
LEGN | Legend Biotech | 5.66% | 12.4B |
EXAS | Exact Sciences | 1.55% | 12.2B |
SRPT | Sarepta Therapeutics | 3.37% | 11.5B |
NBIX | Neurocrine Biosciences | 0.7% | 11.3B |
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Biogen (NASDAQ: BIIB) was reported by HSBC on Wednesday, September 6, 2023. The analyst firm set a price target for 360.00 expecting BIIB to rise to within 12 months (a possible 39.79% upside). 87 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $257.52 last updated September 27, 2023 at 8:00 PM UTC.
There is no dividend information for Biogen.
Biogen’s Q3 earnings are confirmed for Tuesday, October 24, 2023.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.
Open258.440 | Close257.520 |
Vol / Avg.806.443K / 1.004M | Mkt Cap37.295B |
Day Range255.160 - 261.375 | 52 Wk Range194.690 - 334.580 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 4.000 | (EXPECTED) 2023-10-24 | |||||
REV | 2.390B |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.770 | 4.020 | 0.2500 | ||||
REV | 2.370B | 2.456B | 86.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-06 | HSBC | Morten Herholdt | Initiates Coverage On | Buy | Announces | - | 360.00 |
2023-09-05 | Morgan Stanley | Matthew Harrison | Maintains | OverweightOverweight | Raises | 363.00 | 381.00 |
2023-08-29 | RBC Capital | Brian Abrahams | Maintains | OutperformOutperform | Raises | 354.00 | 357.00 |
2023-08-14 | Mizuho | Salim Syed | Maintains | BuyBuy | Lowers | 340.00 | 335.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIIB | Biogen | -0.21% | 37.3B |
LEGN | Legend Biotech | 5.66% | 12.4B |
EXAS | Exact Sciences | 1.55% | 12.2B |
SRPT | Sarepta Therapeutics | 3.37% | 11.5B |
NBIX | Neurocrine Biosciences | 0.7% | 11.3B |
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Biogen (NASDAQ: BIIB) was reported by HSBC on Wednesday, September 6, 2023. The analyst firm set a price target for 360.00 expecting BIIB to rise to within 12 months (a possible 39.79% upside). 87 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $257.52 last updated September 27, 2023 at 8:00 PM UTC.
There is no dividend information for Biogen.
Biogen’s Q3 earnings are confirmed for Tuesday, October 24, 2023.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.
Open258.440 | Close257.520 |
Vol / Avg.806.443K / 1.004M | Mkt Cap37.295B |
Day Range255.160 - 261.375 | 52 Wk Range194.690 - 334.580 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 4.000 | (EXPECTED) 2023-10-24 | |||||
REV | 2.390B |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.770 | 4.020 | 0.2500 | ||||
REV | 2.370B | 2.456B | 86.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-06 | HSBC | Morten Herholdt | Initiates Coverage On | Buy | Announces | - | 360.00 |
2023-09-05 | Morgan Stanley | Matthew Harrison | Maintains | OverweightOverweight | Raises | 363.00 | 381.00 |
2023-08-29 | RBC Capital | Brian Abrahams | Maintains | OutperformOutperform | Raises | 354.00 | 357.00 |
2023-08-14 | Mizuho | Salim Syed | Maintains | BuyBuy | Lowers | 340.00 | 335.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIIB | Biogen | -0.21% | 37.3B |
LEGN | Legend Biotech | 5.66% | 12.4B |
EXAS | Exact Sciences | 1.55% | 12.2B |
SRPT | Sarepta Therapeutics | 3.37% | 11.5B |
NBIX | Neurocrine Biosciences | 0.7% | 11.3B |
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Biogen (NASDAQ: BIIB) was reported by HSBC on Wednesday, September 6, 2023. The analyst firm set a price target for 360.00 expecting BIIB to rise to within 12 months (a possible 39.79% upside). 87 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $257.52 last updated September 27, 2023 at 8:00 PM UTC.
There is no dividend information for Biogen.
Biogen’s Q3 earnings are confirmed for Tuesday, October 24, 2023.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.
Open258.440 | Close257.520 |
Vol / Avg.806.443K / 1.004M | Mkt Cap37.295B |
Day Range255.160 - 261.375 | 52 Wk Range194.690 - 334.580 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 4.000 | (EXPECTED) 2023-10-24 | |||||
REV | 2.390B |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.770 | 4.020 | 0.2500 | ||||
REV | 2.370B | 2.456B | 86.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-06 | HSBC | Morten Herholdt | Initiates Coverage On | Buy | Announces | - | 360.00 |
2023-09-05 | Morgan Stanley | Matthew Harrison | Maintains | OverweightOverweight | Raises | 363.00 | 381.00 |
2023-08-29 | RBC Capital | Brian Abrahams | Maintains | OutperformOutperform | Raises | 354.00 | 357.00 |
2023-08-14 | Mizuho | Salim Syed | Maintains | BuyBuy | Lowers | 340.00 | 335.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIIB | Biogen | -0.21% | 37.3B |
LEGN | Legend Biotech | 5.66% | 12.4B |
EXAS | Exact Sciences | 1.55% | 12.2B |
SRPT | Sarepta Therapeutics | 3.37% | 11.5B |
NBIX | Neurocrine Biosciences | 0.7% | 11.3B |
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Biogen (NASDAQ: BIIB) was reported by HSBC on Wednesday, September 6, 2023. The analyst firm set a price target for 360.00 expecting BIIB to rise to within 12 months (a possible 39.79% upside). 87 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $257.52 last updated September 27, 2023 at 8:00 PM UTC.
There is no dividend information for Biogen.
Biogen’s Q3 earnings are confirmed for Tuesday, October 24, 2023.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.
Open258.440 | Close257.520 |
Vol / Avg.806.443K / 1.004M | Mkt Cap37.295B |
Day Range255.160 - 261.375 | 52 Wk Range194.690 - 334.580 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 4.000 | (EXPECTED) 2023-10-24 | |||||
REV | 2.390B |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.770 | 4.020 | 0.2500 | ||||
REV | 2.370B | 2.456B | 86.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-06 | HSBC | Morten Herholdt | Initiates Coverage On | Buy | Announces | - | 360.00 |
2023-09-05 | Morgan Stanley | Matthew Harrison | Maintains | OverweightOverweight | Raises | 363.00 | 381.00 |
2023-08-29 | RBC Capital | Brian Abrahams | Maintains | OutperformOutperform | Raises | 354.00 | 357.00 |
2023-08-14 | Mizuho | Salim Syed | Maintains | BuyBuy | Lowers | 340.00 | 335.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIIB | Biogen | -0.21% | 37.3B |
LEGN | Legend Biotech | 5.66% | 12.4B |
EXAS | Exact Sciences | 1.55% | 12.2B |
SRPT | Sarepta Therapeutics | 3.37% | 11.5B |
NBIX | Neurocrine Biosciences | 0.7% | 11.3B |
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Biogen (NASDAQ: BIIB) was reported by HSBC on Wednesday, September 6, 2023. The analyst firm set a price target for 360.00 expecting BIIB to rise to within 12 months (a possible 39.79% upside). 87 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $257.52 last updated September 27, 2023 at 8:00 PM UTC.
There is no dividend information for Biogen.
Biogen’s Q3 earnings are confirmed for Tuesday, October 24, 2023.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Biogen Stock (NASDAQ: BIIB) stock price, news, charts, stock research, profile.
Open258.440 | Close257.520 |
Vol / Avg.806.443K / 1.004M | Mkt Cap37.295B |
Day Range255.160 - 261.375 | 52 Wk Range194.690 - 334.580 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 4.000 | (EXPECTED) 2023-10-24 | |||||
REV | 2.390B |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.770 | 4.020 | 0.2500 | ||||
REV | 2.370B | 2.456B | 86.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-06 | HSBC | Morten Herholdt | Initiates Coverage On | Buy | Announces | - | 360.00 |
2023-09-05 | Morgan Stanley | Matthew Harrison | Maintains | OverweightOverweight | Raises | 363.00 | 381.00 |
2023-08-29 | RBC Capital | Brian Abrahams | Maintains | OutperformOutperform | Raises | 354.00 | 357.00 |
2023-08-14 | Mizuho | Salim Syed | Maintains | BuyBuy | Lowers | 340.00 | 335.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BIIB | Biogen | -0.21% | 37.3B |
LEGN | Legend Biotech | 5.66% | 12.4B |
EXAS | Exact Sciences | 1.55% | 12.2B |
SRPT | Sarepta Therapeutics | 3.37% | 11.5B |
NBIX | Neurocrine Biosciences | 0.7% | 11.3B |
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Biogen (NASDAQ: BIIB) was reported by HSBC on Wednesday, September 6, 2023. The analyst firm set a price target for 360.00 expecting BIIB to rise to within 12 months (a possible 39.79% upside). 87 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $257.52 last updated September 27, 2023 at 8:00 PM UTC.
There is no dividend information for Biogen.
Biogen’s Q3 earnings are confirmed for Tuesday, October 24, 2023.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.